Sat.Dec 10, 2022

article thumbnail

STAT+: Bone marrow transplant patients could be spared from ‘bland’ diet, study finds

STAT News

Whenever a hematopoietic cell transplant patient tries to get a family member to sneak food in past the nurses, Federico Stella, a resident hematologist at the University of Milan, remembers. One was a girl who tried to get her sister to bring her a panettone, a Milanese sweet bread usually eaten around the holidays. A week before Christmas, the sister tried to hide the panettone in a bag.

Nurses 145
article thumbnail

Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Medical Xpress

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Emerging class of genetically targeted drugs induce remissions in leukemia patients

STAT News

NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials. Two biotechs — Syndax Pharmaceuticals and Kura Oncology — are developing their own versions of so-called menin inhibitors that have the potential to become effective treatments for certain types of genetically defined acute myeloid leukemia (AML), a rapidly progressing bone mar

Genetics 141
article thumbnail

Extending chemo slashes risk of aggressive childhood leukemia coming back

Medical Xpress

Many children with acute lymphoblastic leukemia (ALL) have a good outcome of their disease. After two years of chemotherapy treatment, 9 out of 10 children are cured. But some children have a more aggressive form of the disease. For example, children with a so-called Ikaros change in the DNA of their leukemia cells have a greater risk of their disease coming back after treatment.

DNA 119
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

STAT+: ‘We’ve got a new target’: Bispecific antibody for multiple myeloma succeeds in mid-stage trial

STAT News

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation. The data, presented Saturday at the annual American Society of Hematology conferences, wowed a crowd of attendees, including clinicians who began excitedly imagining how to use the new drug in practice.

Antibody 132
article thumbnail

Pharmacists migration to Australia and New Zealand gets easier now with Academically.ai

Pharma Tutor

Pharmacists migration to Australia and New Zealand gets easier now with Academically.ai. admin. Sat, 12/10/2022 - 15:42. Academically.ai, We are an Australian healthcare education technology (EdTech) start-up based in Sydney. We provide courses that will prepare pharmacists to practice, getting a job and migrate to Australia and New Zealand. To put it simply, we intend to enter the Indian market because the majority of pharmacists are underpaid, and many are unaware of such vast potential outsid

Marketing 108

More Trending

article thumbnail

Drug found to be effective in difficult-to-treat autoimmune blood disorder

Medical Xpress

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

Drugs 105
article thumbnail

ASH: With immune thrombocytopenia win, argenx proves efgartigimod’s no one-trick pony in autoimmune disease

Fierce Pharma

ASH: With immune thrombocytopenia win, argenx proves efgartigimod’s no one-trick pony in autoimmune disease. fkansteiner. Sat, 12/10/2022 - 09:12.

99
article thumbnail

Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows

Medical Xpress

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remission in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

Trials 98
article thumbnail

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

Fierce Pharma

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle. aliu. Sat, 12/10/2022 - 22:30.

89
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Warmer noses are better at fighting colds: study

Medical Xpress

Chilly weather and common respiratory infections often go hand in hand.

105
105
article thumbnail

Encore: Is lecanemab the Alzheimer's drug that will finally make a difference?

NPR Health - Shots

Researchers say the experimental Alzheimer's drug Lecanemab represents an important advance and is likely to get FDA approval in 2023, despite some safety concerns.

article thumbnail

Medical Imaging for Clinical Trial Sites with Kelie Luby

Clinical Trial Podcast

To learn more about site reads and the role of medical imaging software, I invited Kelie Williams Luby, Vice President of Clinical Trials at Mint Medical. Kelie has 24 years of experience as a clinical trial researcher, first as a medicinal chemist, and for the past 19 years as a clinical trialist in medical imaging-based endpoints. She is passionate about optimizing clinical trial designs while reducing the cognitive burden placed on healthcare providers treating patients in those clinical tria

article thumbnail

New tentative approval for Amneal Pharms drug saxagliptin

Drug Patent Watch

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

STAT+: Progress report on Adicet’s ‘gamma-delta’ T cell therapy shows mixed results on durability of remissions

STAT News

NEW ORLEANS — Adicet Bio generated a good deal of buzz last June with a unique, off-the-shelf therapy made from a special type of T cell that induced complete remissions in patients with advanced and aggressive B cell lymphomas. But an update reported Saturday showed patients starting to relapse, which may raise questions about the so-called gamma-delta T cell therapy’s durability.

article thumbnail

New tentative approval for Teva Pharms drug eltrombopag

Drug Patent Watch

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

Pharmaceutical companies with the most ‘New Chemical Entity’ drugs

Drug Patent Watch

Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs. This is one of the longest exclusivity terms provided by…. The post Pharmaceutical companies with the most ‘New Chemical Entity’ drugs appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40